Welcome to our dedicated page for Spero Therapeuti SEC filings (Ticker: SPRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the real story inside a biotech filing is challenging. Spero Therapeutics’ disclosures weave clinical acronyms, FDA milestones, and royalty math into hundreds of pages. Whether you need the next Spero Therapeutics annual report 10-K simplified or want Spero Therapeutics 8-K material events explained, the details that drive valuation hide in dense footnotes and trial tables.
Stock Titan’s AI-powered analysis turns that maze into clarity. Our platform delivers Spero Therapeutics SEC filings explained simply—from the latest Spero Therapeutics quarterly earnings report 10-Q filing to Spero Therapeutics proxy statement executive compensation. Interactive dashboards surface R&D spend, cash runway, and partnership revenue, while side-by-side comparisons track tebipenem HBr and SPR206 progress across quarters. Need trading intel? We stream Spero Therapeutics Form 4 insider transactions real-time so you never miss Spero Therapeutics executive stock transactions Form 4. Each document is paired with concise AI summaries, keyword search, and instant red-line changes—saving hours and reducing errors.
Analysts, portfolio managers, and life-science investors rely on these insights to:
- Monitor R&D milestones and burn rate without combing through every note
- Compare quarter-over-quarter pipeline updates using our Spero Therapeutics earnings report filing analysis
- Track Spero Therapeutics insider trading Form 4 transactions before catalyst events
- Quickly answer boardroom questions by understanding Spero Therapeutics SEC documents with AI
Spero Therapeutics’ Form 8-K details the voting results of its 12 June 2025 Annual Meeting. A quorum of 40,015,633 shares (71.57%) of the 55.9 million shares outstanding was present.
Board elections: Class II directors Frank E. Thomas, Patrick Vink M.D., and Esther Rajavelu were re-elected through 2028, each receiving roughly 25.7 million votes for and 0.4-2.9 million votes withheld; 13.8 million broker non-votes were recorded.
Auditor ratification: PricewaterhouseCoopers LLP was confirmed as independent auditor for FY 2025 with an overwhelming 39.8 million ‘for’ versus 175 k ‘against’.
Say-on-pay: Executive compensation received shareholder support—25.18 million ‘for’ (96.0%) against 0.64 million ‘against’.
Equity plan amendment: Shareholders approved increasing the 2017 Stock Incentive Plan by 3 million additional shares (22.97 million for / 3.15 million against). This authorizes extra equity that may dilute existing holders once issued but expands flexibility to attract and retain talent.
No financial performance data, earnings guidance, or major strategic transactions were disclosed; the filing is limited to governance and compensation matters.
FAQ
What is the current stock price of Spero Therapeuti (SPRO)?
What is the market cap of Spero Therapeuti (SPRO)?
What is the core focus of Spero Therapeutics?
What product candidates are in Spero Therapeutics' pipeline?
What is tebipenem HBr designed to treat?
How does SPR206 differentiate itself in the market?
Why is addressing multidrug-resistant infections important for Spero Therapeutics?
How does Spero demonstrate its expertise in drug development?
What impact does Spero Therapeutics aim to have on public health?
How does Spero maintain transparency and credibility in its research?
